Lytenava – Talk Bio

Actionable Insights Powered by AI

Outlook Therapeutics Announces Strategic Workforce Reduction to Streamline Operations

4 months ago talkbio0Tagged AMD, Attitude, bevacizumab, biopharmaceutical company, cost-saving measures, Glycogen storage disease type II, Lytenava, restructuring, strategic

Outlook Therapeutics, workforce reduction, biopharmaceutical company, strategic restructuring, cost-saving measures, LYTENAVA, bevacizumab gamma, wet AMD treatment.

Outlook Therapeutics to Resubmit BLA for ONS-5010 Despite Missing Primary Endpoint in NORSE EIGHT Trial

5 months ago talkbio0Tagged AMD, Approved, Attitude, Biologics License Application, Glycogen storage disease type II, Lytenava, New-onset refractory status epilepticus, United States Food and Drug Administration, Wet Age-Related Macular Degeneration

Outlook Therapeutics, ONS-5010, Lytenava, Wet Age-Related Macular Degeneration (wet AMD), Biologics License Application (BLA), NORSE EIGHT Trial, FDA Approval